My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring ...
Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...
Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...
New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.
Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...
News Medical on MSN1d
Cancer-free for 18 years: CAR-T therapy sets new milestone in neuroblastoma treatmentA groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children ...
Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...
Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...
Recent studies show that HIV patients are 10 to 20 times more likely to develop lymphoma compared to individuals without HIV.
The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback